Translation of "Rx drug " (English → French) :

ethical drug | medicinal product subject to medical prescription | prescription drug | prescription medicine | prescription only medicine | prescription-only medicinal product | Rx drug | POM [Abbr.]

drug addiction [ drug abuse | drug-taking | fight against drugs | drug addicts(UNBIS) ]

EU Action Plan on Drugs | EU Action Plan to Combat Drugs | EU Drugs Action Plan | European Union Action Plan on Drugs | European Union Action Plan to Combat Drugs | European Union Drugs Action Plan

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

conducting of drug and alcohol abuse tests | drug abuse tests conduct | conduct drug abuse tests | conducting of drug abuse tests

European Monitoring Centre for Drugs and Drug Addiction [ EMCDDA [acronym] European Monitoring Centre for Drugs ]

drug traffic [ drug trafficking | narcotics traffic | Drugs economy(STW) ]

Cooperation Group to Combat Drug Abuse and Illicit Trafficking in Drugs | Partial Agreement Cooperation Group to Combat Drug Abuse and Illicit Trafficking in Drugs | Pompidou Group

accidental overdose of drug, wrong drug given or taken in error, and drug taken inadvertently accidents in the use of drugs, medicaments and biological substances in medical and surgical procedures (self-inflicted) poisoning, when not specified whether accidental or with intent to harm. Follow legal rulings when available (see note at Y10-Y34).

Definition: This category should be used when two or more psychoactive substances are known to be involved, but it is impossible to assess which substance is contributing most to the disorders. It should also be used when the exact identity of some or even all the psychoactive substances being used is uncertain or unknown, since many multiple drug users themselves often do not know the details of what they are taking. | misuse of drugs NOS

From the Canada's Research-Based Pharmaceutical Companies: John Stewart, Executive Vice-President and General Manager, Purdue Pharma; Marc Desmarais, Vice-President, Federal Government Affairs, Rx&D; Arvind Mani, Director, Regulatory Affairs, Rx&D. From the Canadian Drug Manufacturers Association: Jim Keon, President; John Hems, Director, Regulatory Affairs, Apotex; Kent Major, Director, Regulatory Affairs and Clinical Research, Technilab.

Rx&D and the Canadian Generic Pharmaceutical Association have each contributed $100,000 to the start-up of a national one-stop website for notification of drug shortages.

As well I would honestly say it is a letdown for the generic drug industry and also for Rx and D. Canada came forward with this legislation professing that we would make a difference.

Do they try to make their counterfeit drugs look the same, so if I go on their sites I think I'm getting an Apotex drug or another Rx&D drug?